贝拉普罗斯特和患有慢性病的猫的整体存活率
Hiroyuki Ito1, Takumi Matsuura2, Tadashi Sano3
1Ichikawa General Hospital, Kariya Animal Hospital Group, Chiba 272-0034, Japan.
Veterinary sciences
|July 28, 2023
概括
贝拉普罗斯特治疗显著改善了患有慢性病 (CKD) 的猫的整体存活率. 这一发现支持贝拉普罗斯特作为猫类CKD患者的有益治疗方法,提高寿命.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 总体存活率是治疗猫类慢性病 (CKD) 疗效的关键指标.
- 贝拉普罗斯特已经证明,它有潜力减缓国际脏兴趣协会 (IRIS) 2期和3期CKD的猫的功能下降.
- 贝拉普罗斯特对猫类CKD存活率的影响在很大程度上仍未得到研究.
研究的目的:
- 在现实临床环境中,评估贝拉普罗斯特给药与猫类CKD患者的整体存活率之间的关联.
- 调查贝拉普罗斯特在改善被诊断患有慢性病的猫的寿命方面的临床效用.
主要方法:
- 用单一医院的电子病历进行了一项回顾性队列研究.
- 分析了2017年至2020年间被诊断患有IRIS第3期CKD的134只客户猫的数据.
- 进行了生存分析,包括卡普兰-梅尔曲线,比较接受贝拉普罗斯特治疗的猫与没有接受贝拉普罗斯特治疗的猫.
主要成果:
- 接受贝拉普罗斯特治疗的猫的整体存活时间显著增加 (p = 0.004).
- 以平衡的基线酸盐水平进行的亚队列分析 (n=97) 证实了积极的生存趋势.
- 这些发现在整个研究队列和选定的子队列中是一致的.
结论:
- 贝拉普罗斯特治疗与诊断为慢性病 (CKD) 的猫科动物患者的整体存活率的改善有关.
- 这项研究表明,贝拉普罗斯特作为一种潜在的有价值的治疗选择,可以提高患有CKD的猫的生存结果.
相关概念视频
01:26Kidney Transplant II: Surgical Procedure
36
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
36
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
35
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
35
01:28Chronic Kidney Disease III: Interprofessional Care
42
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
42
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215